If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I have covered Evolus (NASDAQ: EOLS ) twice before in notes for Seeking Alpha, the first time in March 2024 , issuing a "Buy" recommendation, and re-iterating that rating in a more recent note, inThe group is for b ...

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=157198&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

WARREN, N.J., July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial results and provide an update on the company's business and outlook on Thursday, August 7, at 4:30 p.m. ET.To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start ...

Biogen Inc. BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline.In the next few years, Biogen plans to continue investing in multiple modalities and fa ...

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about UroGen’s business, operations, and prospects, including allegations that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it la ...

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET ...

Core Insights - Daré Bioscience, Inc. has developed a proprietary topical formulation of sildenafil, the active ingredient in Viagra, specifically for women, aimed at addressing female sexual arousal issues [1][2] - The product, named DARE to PLAY™, is expected to be available by prescription in the fourth quarter of 2025 [1][5] - A live webinar is scheduled for August 6, 2025, to discuss the clinical evidence supporting the product and its potential impact on women's sexual health [2][3] Company Overview - Daré Bioscience focuses on women's health, aiming to bridge the gap between scientific advancements and practical solutions [1][9] - The company is committed to developing innovative, evidence-based solutions for various women's health issues, including sexual health, contraception, and menopause [9][10] - Daré's first FDA-approved product is XACIATO™, a vaginal gel for bacterial vaginosis, indicating the company's capability in bringing women's health products to market [10] Product Details - DARE to PLAY™ is clinically shown to improve genital blood flow and sexual response in women, distinguishing it from untested compounded products [2][7] - The formulation is designed to deliver sildenafil effectively, addressing a long-standing gap in women's sexual health solutions [2][7] - The product aims to provide a credible, evidence-based option for women experiencing difficulties with sexual arousal, orgasm, and desire [7][9] Webinar Information - The webinar titled "The DARE to PLAY™ Difference: The Sildenafil Cream That Raises the Bar" will feature leading sexual health experts [3][6] - Participants will have the opportunity to join a product alert list to receive updates on the availability of DARE to PLAY™ [5][6] - The event is open to clinicians, investors, and women interested in science-based approaches to improving sexual response [6]

点击上图▲立即收听 " 18—35 岁年轻人的消费榜单前三位，分别是旅游、数码产品和保健养生。 " 文 / 巴九灵（微信公众号：吴晓波频道） "舌苔偏厚，体质寒湿，肝火旺，建议少吃辛辣、冰饮。" 下午时分，26岁的白领小陈对着手机摄像头伸出舌头，屏幕那端的AI医生瞬间给出了这样的反馈。 而看似戏谑的背后，实则是一种集体性的健康觉醒。 由国家统计局等发起的《中国美好生活大调查》显示，18—35岁年轻人的消费榜单前三位分别是旅游、数码产品和保健养生。另外根据知萌咨询 在今年3月的调研数据，Z世代平均每年在健康消费上的支出达到3250.7元。 这不，最近巨头们如火如荼的闪购战，让不少人真切体验了一把奶茶自由。网络上，关于"冰箱塞满奶茶""两天九杯冲上头"的分享不胜枚举，但也 敲响了年轻人的身体警钟。 在"求医AI"前，小陈刚好收到了动态血糖仪APP弹出的"血糖飙升"警告。 公开数据显示，中国咖啡消耗量近10年内增长了167%，消费者偏好带奶、带糖、带小料的花式咖啡；奶茶消费同样也是，超8成用户一周消费2— 3次，甚至高于3次，高频消费的同时还爱搭配软欧包食用。 当这样的"甜蜜轰炸"成为日常，直接催生了一个热词——咖 ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that mea ...